RecruitingPhase 2NCT06798896

RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

RENAISSANCE 2: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of SPN-817 in Adults With Focal Onset Seizures

Sponsor

Supernus Pharmaceuticals, Inc.

Enrollment

216 participants

Start Date

Dec 30, 2024

Study Type

INTERVENTIONAL

Conditions

Focal Onset Seizures

Summary

This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 in adults with focal onset seizures.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a drug called SPN-817 for people with focal onset seizures. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSPN-817

SPN-817 starting at 0.25 mg bid up to 4.00 mg bid

DRUGPlacebo

Placebo, bid

Locations(1)

Medsol Clinical Research Center

Port Charlotte, Florida, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06798896

Related Trials

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

NCT0571610095 locations

SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures

NCT071413291 location